Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serhat Sekmek

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|January 29, 2026
Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort studyFurkan Ceylan, Serhat Sekmek, Ateş Kutay Tenekeci, et al.
Turkish Journal of Medical Sciences|July 21, 2025
Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancerFurkan Ceylan, Didem Şener Dede, Safa Can Efil, et al.
BMC Cancer|July 27, 2025
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinomaOmer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 15, 2025
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, et al.
Immunotherapy|July 4, 2025
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) studySerhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, et al.
The Oncologist|June 27, 2025
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer ConsortiumElif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, et al.
Oncology|July 30, 2024
The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric CancerGökhan Uçar, Serhat Sekmek, İrfan Karahan, et al.
Cancers|March 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek, et al.
Cancers|July 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) StudyMurat Günaltılı, Hatice Bölek, Esma Kaplan Tüzün, et al.
BMC Cancer|May 6, 2025
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysisSedat Yıldırım, Tugba Başoğlu, Akif Doğan, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|January 29, 2026
Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort studyFurkan Ceylan, Serhat Sekmek, Ateş Kutay Tenekeci, et al.
Turkish Journal of Medical Sciences|July 21, 2025
Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancerFurkan Ceylan, Didem Şener Dede, Safa Can Efil, et al.
BMC Cancer|July 27, 2025
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinomaOmer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 15, 2025
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, et al.
Immunotherapy|July 4, 2025
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) studySerhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, et al.
The Oncologist|June 27, 2025
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer ConsortiumElif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, et al.
Oncology|July 30, 2024
The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric CancerGökhan Uçar, Serhat Sekmek, İrfan Karahan, et al.
Cancers|March 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek, et al.
Cancers|July 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) StudyMurat Günaltılı, Hatice Bölek, Esma Kaplan Tüzün, et al.
BMC Cancer|May 6, 2025
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysisSedat Yıldırım, Tugba Başoğlu, Akif Doğan, et al.
Pageof 4